Peter Klein Net Worth

Peter Klein biography

Dr. Peter Justin Klein M.D. serves as Independent Director of the Company.D. serves as Independent Director of the Company. serves as Independent Director of the Company. Klein currently serves as a managing director of Vensana Capital Management, LLC, a position he has held since December 2018. Dr. Klein previously served as a partner at New Enterprise Associates, Inc. from February 2012 to December 2018. He has served on the board of directors of Senseonics Holdings, Inc. since December 2015. Dr. Klein received an A.B. in economics and a B.S. in biological anthropology and anatomy from Duke University, a J.D. from Harvard Law School and an M.D. from Duke University. Our Board of Directors believes that Dr. Klein is qualified to serve as a director based on his extensive experience in the healthcare industry.

What is the salary of Peter Klein?

As the Independent Director of PhaseBio Pharmaceuticals, the total compensation of Peter Klein at PhaseBio Pharmaceuticals is $202,892. There are 7 executives at PhaseBio Pharmaceuticals getting paid more, with Jonathan Mow having the highest compensation of $1,203,070.

How old is Peter Klein?

Peter Klein is 42, he's been the Independent Director of PhaseBio Pharmaceuticals since 2009. There are 18 older and no younger executives at PhaseBio Pharmaceuticals. The oldest executive at PhaseBio Pharmaceuticals, Inc. is Nancy Hutson, 70, who is the Independent Director.

What's Peter Klein's mailing address?

Peter's mailing address filed with the SEC is C/O PHASEBIO PHARMACEUTICALS, INC., 1 GREAT VALLEY PARKWAY, SUITE 30, MALVERN, PA, 19355.

Insiders trading at PhaseBio Pharmaceuticals

Over the last 6 years, insiders at PhaseBio Pharmaceuticals have traded over $361,083 worth of PhaseBio Pharmaceuticals stock and bought 24,000 units worth $81,960 . The most active insiders traders include Clay Thorp, Enterprise Associates 13 Lp... y Nancy J Hutson. On average, PhaseBio Pharmaceuticals executives and independent directors trade stock every 52 days with the average trade being worth of $5,138. The most recent stock trade was executed by Clay Thorp on 19 May 2023, trading 3,750 units of PHAS stock currently worth $263.

What does PhaseBio Pharmaceuticals do?

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

PhaseBio Pharmaceuticals executives and stock owners

PhaseBio Pharmaceuticals executives and other stock owners filed with the SEC include:

• Jonathan Mow,
  Chief Executive Officer, Director
• Jonathan P. Mow,
  Pres, CEO & Director
• John Lee,
  Chief Medical Officer
• John Sharp,
  Chief Financial Officer
• Dr. John S. Lee,
  Chief Medical Officer
• John P. Sharp,
  Chief Financial Officer
• Clay Thorp,
  Co-Founder, Independent Chairman of the Board
• Peter Klein,
  Independent Director
• Nancy Hutson,
  Independent Director
• Richard van den Broek,
  Independent Director
• Caroline Loewy,
  Independent Director
• Edmund Harrigan,
  Independent Director
• Alex Sapir,
  Independent Director
• Michael York,
  Vice President - Corporate Development and Commercial Strategy
• Jim Ballance,
  Vice President - Research and Scientific Affairs
• Susan Arnold,
  Vice President - Preclinical and Chemistry, Manufacturing and Controls
• Kristophe Hanson,
  Vice President - Head of Legal, Corporate Secretary
• Glen Burkhardt,
  Vice President - Human Resources
• Jonathan J. Birchall,
  Chief Commercial Officer
• Glen Burkhardt,
  VP of HR
• Lauren Richardson,
  Global Head of Regulatory Affairs & Quality Assurance
• Kristopher L. Hanson,
  VP, Head of Legal & Corp. Sec.
• Bibhash Mukhopadhyay,
  Director
• David James Ballance,
  VP, Research and Sci. Affairs
• Linda Tufts,
  Director
• William D. Humphries,
  Director
• Jonathan Birchall,
  Chief Commercial Officer
• Enterprise Associates 13 Lp...,